We are excited to let you know the Deucrictibant study is now entering Phase 3 and open label studies in order to hopefully have it registered in the future.
Deucrictibant is a painless, effective oral treatment for acute attacks and we are calling on patients to register and be part of the study now.
This medication is a game changer when it comes to treatment for those who are uncomfortable with injections. It is a painless and convenient treatment and the study is open to patients 12 and older. You can even be on prophylactic meds and there are limited face to face visits or journal requirements.
For more information visit our Clinical Trials page here –Patients & Carers – HAE – Australasia and scroll down to the clinical trials tab.
Its so important we have as many people join this study as possible to improve the options for care for HAE patients.